{"entity":{"id":"ala-101","kind":"drug","name":"ALA-101","aka":["CAR19-iNKT"],"tldr":"ALA-101 is an experimental allogeneic CAR-iNKT cell therapy from Arovella Therapeutics, in phase 1 trials for CD19-positive B-cell lymphoma, CD19-positive leukaemia and non-Hodgkin lymphoma.","summary":"ALA-101 (CAR19-iNKT) is an allogeneic CAR-iNKT cell therapy from Arovella Therapeutics. Off-the-shelf invariant natural killer T (iNKT) cells carrying a chimeric antigen receptor against CD19; the company says lymphomas that also express CD1d bound to a glycolipid can be recognised by the iNKT cells' own receptor, making them dual targeting. Its furthest stage is phase 1, for CD19-positive B-cell lymphoma, CD19-positive leukaemia and non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07518329 recruiting; registry start date 19 October 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Arovella Therapeutics: arovella.com","url":"https://www.arovella.com/ala-101-car19-inkt"},{"label":"Arovella Therapeutics: arovella.com","url":"https://www.arovella.com/ala-101-car19-inkt"},{"label":"Arovella Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07518329"},{"label":"ClinicalTrials.gov: trials of ALA-101","url":"https://clinicaltrials.gov/search?intr=ALA-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","leukaemia"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["arovella-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07518329"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ALA-101","modality":"Allogeneic CAR-iNKT cell therapy","mechanism":"Off-the-shelf invariant natural killer T (iNKT) cells carrying a chimeric antigen receptor against CD19; the company says lymphomas that also express CD1d bound to a glycolipid can be recognised by the iNKT cells' own receptor, making them dual targeting.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ala-101/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"arovella-therapeutics","kind":"company","name":"Arovella Therapeutics","route":"/companies/arovella-therapeutics/"}],"trial":[{"id":"nct07518329","kind":"trial","name":"Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.","route":"/trials/nct07518329/"}]}}